ProLynx announces PLX039, a hydrogel-microsphere drug delivery system that supports once-monthly administration of a GLP-1 receptor agonist
SAN FRANCISCO, June 12, 2017 (GLOBE NEWSWIRE) -- In a late-breaking abstract at the 77th American Diabetes Association meeting in San Diego, ProLynx LLC announced a novel drug delivery system to support once-monthly subcutaneous (SC) administration of a GLP-1 receptor agonist (GLP-1RA) called PLX039 for the treatment of Type 2 diabetes (T2D). The work will be published in ACS Chemical Biology.
GLP-1RAs have emerged as an important standard-of-care drug class for the treatment of Type 2 diabetes and are projected to command a $12 Bill market by 2024. These agonists auto-regulate blood glucose concentration, have anti-obesity effects, and may reduce risks for adverse cardiovascular events in patients with T2D. Currently, there are three once- or twice- daily and three once-weekly GLP-1RAs approved by the FDA; an additional once-weekly agonist and a long-acting osmotic pump delivery system are in late stage trials. Yet, poor medication adherence and persistence remain as major factors leading to failure of glycemic control in almost 50% of T2D patients. Now, ProLynx has used its half-life extension platform to develop a monthly-administered GLP-1RA. Compared to weekly-administered agonists, obvious benefits are believed to include greater patient convenience, compliance and persistence.
Daniel Santi, co-founder and President of ProLynx, said: "This is the first GLP-1RA that does not require huge doses of a drug meant for weekly administration to maintain therapeutic levels over a monthly period." Santi added: "PLX039 should find a dose-interval sweet-spot with its once-monthly administration. Some patients will find that a once-weekly dosing interval is too short, and will not want to have a long-acting osmotic pump implanted; for these patients, the once monthly GLP-1 receptor agonist PLX039 should be just right."
In the ProLynx half-life extension platform, a drug is tethered to hydrogel microspheres by a self-cleaving linker that is pre-programmed to release the drug at a pre-determined rate. After SC injection, the drug is slowly released from the microsphere depot into the systemic circulation. ProLynx attached their peptidic GLP-1RA - a stabilized analog of exenatide - to its hydrogel microspheres. After SC injection to rodents the GLP-1RA showed a serum half-life of one month. Monthly injections of the formulation in diabetic rats showed identical glucoregulatory effects as continuously infused exenatide, and simulation of the pharmacokinetics indicate it should serve well as a once-a-month treatment for T2D in humans.
About ProLynx. ProLynx LLC is a privately held biotechnology company developing proprietary drug delivery systems for half-life extension of proteins, peptides and small molecules. The company is seeking to apply its technology to extend half-lives of drug candidates of pharmaceutical companies, and to improve properties of off-patent therapeutics. ProLynx has a monthly GLP-1 receptor agonist and a subcutaneous long-acting octreotide in its pre-clinical portfolio, and a PEG~SN-38 in Phase 1 clinical trials. The company is located in San Francisco, CA. Further information about the company may be found at www.ProLynxllc.com .
Contact: Eric Schneider: Eric@ProLynxllc.com Or BD@ProLynxllc.com 415-552-5306
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Globenewswire
Magna International Inc.19.7.2018 21:36 | pressemeddelelse
Second Quarter 2018 Results Conference Call
Crown Bioscience Inc.19.7.2018 15:05 | pressemeddelelse
CrownBio Supports Excellence in Translational Research with Grant Award that Funds Innovative PDX Model Development in Immuno-Oncology
ForgeRock, Inc.19.7.2018 10:03 | pressemeddelelse
ForgeRock Opens Up Open Banking
David Crosby18.7.2018 18:06 | pressemeddelelse
David Crosby Announces Intent to License His Name to the Cannabis Industry
Seaborn Networks18.7.2018 17:02 | pressemeddelelse
Telecom Argentina's landing station and backhaul are selected for ARBR submarine cable system between Argentina & Brazil
Mitratech18.7.2018 15:04 | pressemeddelelse
Salim Ismail Announced as Keynote Speaker at Mitratech's Interact 2018 Conference
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum